KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Free Cash Flow: 2009-2024

Historic Free Cash Flow for Novavax (NVAX) over the last 16 years, with Dec 2024 value amounting to -$100.4 million.

  • Novavax's Free Cash Flow rose 172.36% to $105.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$383.8 million, marking a year-over-year decrease of 246.26%. This contributed to the annual value of -$100.4 million for FY2024, which is 86.93% up from last year.
  • As of FY2024, Novavax's Free Cash Flow stood at -$100.4 million, which was up 86.93% from -$767.7 million recorded in FY2023.
  • In the past 5 years, Novavax's Free Cash Flow ranged from a high of $268.4 million in FY2021 and a low of -$767.7 million during FY2023.
  • For the 3-year period, Novavax's Free Cash Flow averaged around -$457.7 million, with its median value being -$505.0 million (2022).
  • Per our database at Business Quant, Novavax's Free Cash Flow soared by 376.71% in 2021 and then tumbled by 288.12% in 2022.
  • Over the past 5 years, Novavax's Free Cash Flow (Yearly) stood at -$97.0 million in 2020, then soared by 376.71% to $268.4 million in 2021, then plummeted by 288.12% to -$505.0 million in 2022, then crashed by 52.03% to -$767.7 million in 2023, then soared by 86.93% to -$100.4 million in 2024.